

Josep Comin-Colet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1811521/publications.pdf>

Version: 2024-02-01

165
papers

8,831
citations

81434

41
h-index

54771

88
g-index

184
all docs

184
docs citations

184
times ranked

7880
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic impact of late gadolinium enhancement at the right ventricular insertion points in non-ischaemic dilated cardiomyopathy. <i>European Heart Journal Cardiovascular Imaging</i> , 2023, 24, 346-353.	0.5	9
2	The relationship between self-care, long-term mortality, and heart failure hospitalization: insights from a real-world cohort study. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 116-126.	0.4	18
3	Burden of cardiovascular risk factors and disease in five Asian groups in Catalonia: a disaggregated, population-based analysis of 121 000 first-generation Asian immigrants. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 916-924.	0.8	23
4	Factores clave para modelos de atención a la insuficiencia cardiaca. Una visión integradora y multidisciplinar. <i>REC: CardioClinics</i> , 2022, 57, 24-38.	0.1	1
5	Effectiveness of telemedicine in patients with heart failure according to frailty phenotypes: Insights from the iCOR randomised controlled trial. <i>European Journal of Internal Medicine</i> , 2022, 96, 49-59.	1.0	14
6	Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. <i>European Heart Journal</i> , 2022, 43, 1320-1330.	1.0	26
7	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 20.	0.8	2
8	Prognostic Value of the Acute-to-Chronic Glycemic Ratio at Admission in Heart Failure: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6.	1.0	4
9	Ventricular Arrhythmias and Sudden Death in Nonischemic Dilated Cardiomyopathy: Matter of Sex or Scar?. <i>Journal of Cardiac Failure</i> , 2022, 28, 1278-1286.	0.7	1
10	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 184-197.	1.9	75
11	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	2.9	15
12	Responder analysis for improvement in six-minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, , .	2.9	8
13	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	1.6	65
14	Usefulness of Impella support in different clinical settings in cardiogenic shock.. <i>Journal of Geriatric Cardiology</i> , 2022, 19, 115-124.	0.2	2
15	Usefulness of telemedicine-based heart failure monitoring according to "eHealth literacy" domains: Insights from the iCOR randomized controlled trial. <i>European Journal of Internal Medicine</i> , 2022, 101, 56-67.	1.0	3
16	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2976.	1.0	5
17	Amphilimus- versus everolimus-eluting stents in patients with diabetes mellitus: 5-year follow-up of the RESERVOIR trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	0
18	Renin-angiotensin-aldosterone inhibition in chronic heart failure: From theory into practice. <i>European Journal of Internal Medicine</i> , 2022, , .	1.0	0

#	ARTICLE	IF	CITATIONS
19	Iron deficiency and supplementation therapy in heart failure. <i>Nature Reviews Cardiology</i> , 2022, 19, 571-572.	6.1	1
20	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. <i>European Journal of Heart Failure</i> , 2021, 23, 919-932.	2.9	46
21	Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 533-543.	0.4	3
22	Impact on clinical outcomes and health costs of deranged potassium levels in patients with chronic cardiovascular, metabolic, and renal conditions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 312-320.	0.4	3
23	OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 127-135.	2.9	50
24	Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 201.	0.4	0
25	Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 1013-1022.	0.4	4
26	Neurohormonal activation induces intracellular iron deficiency and mitochondrial dysfunction in cardiac cells. <i>Cell and Bioscience</i> , 2021, 11, 89.	2.1	16
27	The Future of Telemedicine in the Management of Heart Failure Patients. <i>Cardiac Failure Review</i> , 2021, 7, e11.	1.2	32
28	Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2890-2905.	1.2	82
29	No inferioridad de la titulaci3n de enfermera de insuficiencia cardiaca en comparaci3n con la de cardi3logo de insuficiencia cardiaca. Ensayo aleatorizado multic3ntrico ETIFIC. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 533-543.	0.6	34
30	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 1677-1686.	2.9	11
31	Atrial Fibrillation in Heart Failure Is Associated with High Levels of Circulating microRNA-199a-5p and 2265p and a Defective Regulation of Intracellular Calcium and Cell-to-Cell Communication. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10377.	1.8	11
32	Ambulatory intravenous treatment of decompensated heart failure: An effective, safe and cost-effective approach. <i>REC: CardioClinics</i> , 2021, 56, 7-13.	0.1	1
33	Hospitalization-related economic impact of patients with cardiogenic shock in a high-complexity reference centre. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 50-53.	0.4	10
34	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	1.0	71
35	First Bicaval Valve Implantation in a Heart Transplant Patient to Treat Severe Symptomatic Tricuspid Regurgitation. <i>Circulation: Heart Failure</i> , 2021, 14, e008491.	1.6	0
36	Blood Differential Gene Expression in Patients with Chronic Heart Failure and Systemic Iron Deficiency: Pathways Involved in Pathophysiology and Impact on Clinical Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 4937.	1.0	6

#	ARTICLE	IF	CITATIONS
37	Coronary Endothelium-Dependent Vasomotor Function After Drug-Eluting Stent and Bioresorbable Scaffold Implantation. <i>Journal of the American Heart Association</i> , 2021, 10, e022123.	1.6	4
38	Performance of Three Measures of Comorbidity in Predicting Critical COVID-19: A Retrospective Analysis of 4607 Hospitalized Patients. <i>Risk Management and Healthcare Policy</i> , 2021, Volume 14, 4729-4737.	1.2	13
39	Quality of life and disease experience in patients with heart failure with reduced ejection fraction in Spain: a mixed-methods study. <i>BMJ Open</i> , 2021, 11, e053216.	0.8	11
40	Implications of the 2021 ESC Cardiovascular Risk Classification among 283,000 European Immigrants Living in a Low-Risk Region: A Population-Based Analysis in Catalonia. <i>Archives of Medical Science</i> , 2021, , ,	0.4	0
41	Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial. <i>Journal of Telemedicine and Telecare</i> , 2020, 26, 64-72.	1.4	38
42	Nursing knowledge of the principles of self-care of heart failure in primary care: a multicentre study. <i>Scandinavian Journal of Caring Sciences</i> , 2020, 34, 710-718.	1.0	6
43	Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 361-367.	0.4	2
44	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. <i>International Journal of Infectious Diseases</i> , 2020, 101, 290-297.	1.5	33
45	Use of potassium-binder patiromer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-4.	0.3	2
46	<p>Real-World Epidemiology of Potassium Derangements Among Chronic Cardiovascular, Metabolic and Renal Conditions: A Population-Based Analysis</p>. <i>Clinical Epidemiology</i> , 2020, Volume 12, 941-952.	1.5	8
47	Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 329.	1.0	30
48	Association of fractalkine with functional severity of heart failure and impact on clopidogrel efficacy in patients with ischemic heart disease. <i>Thrombosis Research</i> , 2020, 196, 215-221.	0.8	1
49	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020, 396, 1895-1904.	6.3	425
50	Tako-tsubo syndrome associated with COVID-19. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 846.	0.4	8
51	Sympathetic activation and outcomes in chronic heart failure: Does the neurohormonal hypothesis apply to mid-range and preserved ejection fraction patients?. <i>European Journal of Internal Medicine</i> , 2020, 81, 60-66.	1.0	14
52	Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain. <i>Journal of Medical Economics</i> , 2020, 23, 1418-1424.	1.0	9
53	Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS). <i>ESC Heart Failure</i> , 2020, 7, 4448-4457.	1.4	9
54	Gender Differences in Health-Related Quality of Life in Patients with Systolic Heart Failure: Results of the VIDA Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2825.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 1236-1245.	1.6	81
56	First episode of acute heart failure: Can we already predict the risk of short-term mortality?. <i>European Journal of Internal Medicine</i> , 2020, 77, 30-31.	1.0	1
57	Rationale and study design of <scp>OUTSTEP–HF</scp>: a randomised controlled study to assess the effect of sacubitril/valsartan and enalapril on physical activity measured by accelerometry in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 1724-1733.	2.9	8
58	Validation of the Spanish version of the questionnaire on Patient Empowerment in Long-Term Conditions. <i>PLoS ONE</i> , 2020, 15, e0233338.	1.1	6
59	Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF–ID study. <i>International Journal of Clinical Practice</i> , 2020, 74, e13584.	0.8	6
60	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 4-22.	0.8	49
61	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 999-1005.	2.9	71
62	Iron Deficiency: Impact on Functional Capacity and Quality of Life in Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2020, 9, 1199.	1.0	37
63	<p>Performance of Comprehensive Risk Adjustment for the Prediction of In-Hospital Events Using Administrative Healthcare Data: The Queral Indices</p>. <i>Risk Management and Healthcare Policy</i> , 2020, Volume 13, 271-283.	1.2	16
64	Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. <i>Advances in Therapy</i> , 2020, 37, 1960-2002.	1.3	11
65	Use of intravenous iron in patients with iron deficiency and chronic heart failure: Real-world evidence. <i>European Journal of Internal Medicine</i> , 2020, 80, 91-98.	1.0	10
66	Short term prognosis of heart failure after first hospital admission. <i>Medicina Cl�nica</i> , 2020, 154, 37-44.	0.3	6
67	An�lisis econ�mico del tratamiento ambulatorio intermitente con levosimend�n de la insuficiencia cardiaca avanzada en Espa�a. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 361-367.	0.6	8
68	Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial�RON Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014254.	1.6	58
69	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. <i>Cardiac Failure Review</i> , 2020, 6, e19.	1.2	37
70	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure��Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1834.	1.0	14
71	Short length of hospitalization in patients with acute heart failure entails a high risk of readmission: True or false? Insights from the LOHRCA study. <i>European Journal of Internal Medicine</i> , 2019, 70, 13-15.	1.0	1
72	Angiotensin��Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485

#	ARTICLE	IF	CITATIONS
73	Heart failure admission across glomerular filtration rate categories in a community cohort of 125,053 individuals over 60 years of age. Hypertension Research, 2019, 42, 2013-2020.	1.5	8
74	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	0.8	42
75	Epidemiology, risk factors, and opportunities for prevention of cardiovascular disease in individuals of South Asian ethnicity living in Europe. Atherosclerosis, 2019, 286, 105-113.	0.4	40
76	Breast Arterial Calcium. JACC: Cardiovascular Imaging, 2019, 12, 2538-2548.	2.3	21
77	Efficacy of a nurse-led lipid-lowering secondary prevention intervention in patients hospitalized for ischemic heart disease: A pilot randomized controlled trial. European Journal of Cardiovascular Nursing, 2019, 18, 366-374.	0.4	8
78	Significant and constant increase in hospitalization due to heart failure in Spain over 15-year period. European Journal of Internal Medicine, 2019, 64, 48-56.	1.0	17
79	Cardiovascular risk factors and disease among non-European immigrants living in Catalonia. Heart, 2019, 105, heartjnl-2018-314436.	1.2	16
80	Socioeconomic status, life expectancy and mortality in a universal healthcare setting: An individual-level analysis of 6 million Catalan residents. Preventive Medicine, 2019, 123, 91-94.	1.6	27
81	Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification. European Journal of Haematology, 2019, 102, 509-515.	1.1	15
82	Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron Deficiency More Than a Comorbidity?. Journal of the American Heart Association, 2019, 8, e010887.	1.6	27
83	Individual income, mortality and healthcare resource use in patients with chronic heart failure living in a universal healthcare system: A population-based study in Catalonia, Spain. International Journal of Cardiology, 2019, 277, 250-257.	0.8	34
84	Reduced levels of vasopressin, an independent mechanism in the obesity paradox in patients with chronic heart failure: Insights from the DAMOCLES study. International Journal of Cardiology, 2019, 276, 171-176.	0.8	8
85	Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period. ESC Heart Failure, 2019, 6, 174-181.	1.4	43
86	Planning to reduce 30-day adverse events after discharge of frail elderly patients with acute heart failure: design and rationale for the DEED FRAIL-AHF trial. Emergencias, 2019, 31, 27-35.	0.6	20
87	Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. European Journal of Heart Failure, 2018, 20, 1128-1136.	2.9	134
88	Iron overload cardiomyopathy. Current Opinion in Cardiology, 2018, 33, 334-340.	0.8	23
89	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. European Journal of Heart Failure, 2018, 20, 125-133.	2.9	317
90	Iron deficiency and red cell indices in patients with heart failure. European Journal of Heart Failure, 2018, 20, 114-122.	2.9	54

#	ARTICLE	IF	CITATIONS
91	Clinical practices and attitudes regarding the diagnosis and management of heart failure: findings from the CORE Needs Assessment Survey. <i>ESC Heart Failure</i> , 2018, 5, 172-183.	1.4	12
92	Repetitive levosimendan treatment in the management of advanced heart failure. <i>European Heart Journal Supplements</i> , 2018, 20, I11-I20.	0.0	23
93	Coronary Artery Calcium: Recommendations for Risk Assessment in Cardiovascular Prevention Guidelines. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 89.	0.4	13
94	Associations between self-reported periodontal disease, assessed using a very short questionnaire, cardiovascular disease events and all-cause mortality in a contemporary multi-ethnic population: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>Atherosclerosis</i> , 2018, 278, 110-116.	0.4	9
95	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. <i>European Journal of Heart Failure</i> , 2018, 20, 1664-1672.	2.9	92
96	The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>Atherosclerosis</i> , 2018, 278, 217-225.	0.4	30
97	Synergistic Opportunities in the Interplay Between Cancer Screening and Cardiovascular Disease Risk Assessment. <i>Circulation</i> , 2018, 138, 727-734.	1.6	69
98	Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 206.	0.7	18
99	Communication issues in nutritional observational research. <i>Preventive Medicine</i> , 2018, 115, 76-82.	1.6	8
100	Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. <i>American Heart Journal</i> , 2018, 202, 76-83.	1.2	7
101	The prognostic value of high sensitivity C-reactive protein in a multi-ethnic population after >10 years of follow-up: The Multi-Ethnic Study of Atherosclerosis (MESA). <i>International Journal of Cardiology</i> , 2018, 264, 158-164.	0.8	18
102	Testosterone Replacement Therapy in Deficient Patients With Chronic Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 543-550.	1.0	16
103	Chronic Heart Failure Care and Costs. <i>JACC: Heart Failure</i> , 2018, 6, 723-724.	1.9	0
104	Iron deficiency in chronic heart failure: case-based practical guidance. <i>ESC Heart Failure</i> , 2018, 5, 764-771.	1.4	43
105	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
106	Coronary Artery Calcium Score: the "Mammogram" of the Heart?. <i>Current Cardiology Reports</i> , 2018, 20, 70.	1.3	17
107	Transcultural adaptation and validation of the patient empowerment in long-term conditions questionnaire. <i>BMC Health Services Research</i> , 2017, 17, 324.	0.9	11
108	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	0.8	42

#	ARTICLE	IF	CITATIONS
109	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <i>International Journal of Cardiology</i> , 2017, 243, 389-395.	0.8	26
110	Design of a multicentre randomized controlled trial to assess the safety and efficacy of dose titration by specialized nurses in patients with heart failure. ETIFIC study protocol. <i>ESC Heart Failure</i> , 2017, 4, 507-519.	1.4	8
111	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. <i>American Journal of Hematology</i> , 2017, 92, 1068-1078.	2.0	290
112	El déficit de hierro es un determinante de la capacidad funcional y de la calidad de vida a los 30 días tras un síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 363-370.	0.6	9
113	Defining quantification methods and optimizing protocols for microarray hybridization of circulating microRNAs. <i>Scientific Reports</i> , 2017, 7, 7725.	1.6	52
114	Management of anemia in patients with congestive heart failure. <i>American Journal of Hematology</i> , 2017, 92, 88-93.	2.0	43
115	Iron Deficiency Is a Determinant of Functional Capacity and Health-related Quality of Life 30 Days After an Acute Coronary Syndrome. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 363-370.	0.4	7
116	Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). <i>BMJ Open</i> , 2017, 7, e018719.	0.8	40
117	Transcatheter aortic valve implantation and surgical aortic valve replacement among hospitalized patients with and without type 2 diabetes mellitus in Spain (2014-2015). <i>Cardiovascular Diabetology</i> , 2017, 16, 144.	2.7	24
118	Real world heart failure epidemiology and outcome: A population-based analysis of 88,195 patients. <i>PLoS ONE</i> , 2017, 12, e0172745.	1.1	127
119	No benefit from the obesity paradox for diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 851-858.	2.9	49
120	Medical resource use and expenditure in patients with chronic heart failure: a population-based analysis of 88 195 patients. <i>European Journal of Heart Failure</i> , 2016, 18, 1132-1140.	2.9	132
121	Iron Deficiency in Patients With Acute Coronary Syndrome: Prevalence and Predisposing Factors. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 615-617.	0.4	2
122	Déficit de hierro en pacientes con síndrome coronario agudo: prevalencia y factores predisponentes. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 615-617.	0.6	9
123	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	0.7	12
124	Iron deficiency and risk of early readmission following hospitalization for acute heart failure. Reply. <i>European Journal of Heart Failure</i> , 2016, 18, 881-881.	2.9	27
125	Ischemic aetiology, self-reported frailty, and gender with respect to cognitive impairment in chronic heart failure patients. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 163.	0.7	27
126	Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 798-802.	2.9	84

#	ARTICLE	IF	CITATIONS
127	Transitions of Care Between Acute and Chronic Heart Failure: Critical Steps in the Design of a Multidisciplinary Care Model for the Prevention of Rehospitalization. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 951-961.	0.4	30
128	The Limitations of the 6-Minute Walk Test as a Measurement Tool in Chronic Heart Failure Patients. Response. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 630.	0.4	0
129	Iron Status in Chronic Heart Failure: Impact on Symptoms, Functional Class and Submaximal Exercise Capacity. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 247-255.	0.4	33
130	Effect of Permanent Atrial Fibrillation on Cognitive Function in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 233-239.	0.7	30
131	Health-related Quality of Life of Patients With Chronic Systolic Heart Failure in Spain: Results of the VIDA-IC Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 256-271.	0.4	33
132	Impact on clinical events and healthcare costs of adding telemedicine to multidisciplinary disease management programmes for heart failure: Results of a randomized controlled trial. <i>Journal of Telemedicine and Telecare</i> , 2016, 22, 282-295.	1.4	93
133	Patient risk factors for developing a drug-related problem in a cardiology ward. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 9.	0.9	34
134	A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 846-851.	0.4	15
135	A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. <i>Heart Failure Reviews</i> , 2015, 20, 545-552.	1.7	10
136	Effect of Correction of Anemia on Echocardiographic and Clinical Parameters in Patients With Aortic Stenosis Involving a Three-Cuspid Aortic Valve and Normal Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2015, 116, 270-274.	0.7	9
137	Differences in neurohormonal activity partially explain the obesity paradox in patients with heart failure: The role of sympathetic activation. <i>International Journal of Cardiology</i> , 2015, 181, 120-126.	0.8	26
138	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	1.0	902
139	Vitamin B12 and folate deficiency in chronic heart failure. <i>Heart</i> , 2015, 101, 302-310.	1.2	26
140	Rationale and design of the CONFIRM-CHF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, 52-58.	1.4	38
141	Health Care and Nonhealth Care Costs in the Treatment of Patients With Symptomatic Chronic Heart Failure in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 643-650.	0.4	38
142	Tratamiento de la insuficiencia cardiaca con funci3n sist3lica deprimida: situaci3n actual en Espa3a. Resultados del estudio VIDA-IC. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 769-770.	0.6	15
143	Efficacy of an Integrated Hospital-primary Care Program for Heart Failure: A Population-based Analysis of 56742 Patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 283-293.	0.4	39
144	Current Situation of Management of Systolic Heart Failure in Spain: VIDA-IC Study Results. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 769-770.	0.4	4

#	ARTICLE	IF	CITATIONS
145	Prognostic Value of NT-proBNP and an Adapted Monin Score in Patients With Asymptomatic Aortic Stenosis. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 52-57.	0.4	8
146	Costes sanitarios y no sanitarios de personas que padecen insuficiencia cardiaca cr�nica sintom�tica en Espa�a. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 643-650.	0.6	103
147	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. <i>International Journal of Cardiology</i> , 2014, 174, 268-275.	0.8	147
148	The additive burden of iron deficiency in the cardiorenal�anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014, 16, 655-662.	2.9	59
149	Explicit and Implicit Emotional Expression in Bulimia Nervosa in the Acute State and after Recovery. <i>PLoS ONE</i> , 2014, 9, e101639.	1.1	15
150	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. <i>International Journal of Cardiology</i> , 2013, 168, 3878-3883.	0.8	30
151	Iron deficiency in chronic heart failure: An international pooled analysis. <i>American Heart Journal</i> , 2013, 165, 575-582.e3.	1.2	532
152	HIGH SOLUBLE TRANSFERRIN RECEPTOR IN PATIENTS WITH SYSTOLIC HEART FAILURE: A MEASURE OF IRON DEFICIENCY AND A STRONG PREDICTOR OF MORTALITY. <i>Journal of the American College of Cardiology</i> , 2013, 61, E749.	1.2	2
153	Survival in Mediterranean Ambulatory Patients With Chronic Heart Failure. A Population-based Study. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 539-544.	0.4	7
154	High-intensity vs. sham inspiratory muscle training in patients with chronic heart failure: a prospective randomized trial. <i>European Journal of Heart Failure</i> , 2013, 15, 892-901.	2.9	64
155	Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. <i>European Journal of Heart Failure</i> , 2013, 15, 1164-1172.	2.9	165
156	The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. <i>European Heart Journal</i> , 2013, 34, 30-38.	1.0	139
157	Rapid Point-of-Care NT-proBNP Optimal Cut-off Point for Heart Failure Diagnosis in Primary Care. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 613-619.	0.4	12
158	Punto de corte �ptimo de NT-proBNP para el diagn�stico de insuficiencia cardiaca mediante un test de determinaci�n r�pida en atenci�n primaria. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 613-619.	0.6	31
159	Effects of Preoperative Intravenous Erythropoietin Plus Iron on Outcome in Anemic Patients After Cardiac Valve Replacement. <i>American Journal of Cardiology</i> , 2012, 110, 1021-1026.	0.7	100
160	Iron therapy alone or in combination with erythropoietin in surgical and medical cardiac patients. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2012, 12, 143-149.	0.2	2
161	Validaci�n de la versi�n espa�ola del Kansas City Cardiomyopathy Questionnaire. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 51-58.	0.6	34
162	Validation of the Spanish Version of the Kansas City Cardiomyopathy Questionnaire. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 51-58.	0.4	15

#	ARTICLE	IF	CITATIONS
163	Iron deficiency and anaemia in heart failure: understanding the FAIR&HF trial. <i>European Journal of Heart Failure</i> , 2010, 12, 1159-1162.	2.9	38
164	A Pilot Evaluation of the Long-term Effect of Combined Therapy With Intravenous Iron Sucrose and Erythropoietin in Elderly Patients With Advanced Chronic Heart Failure and Cardio-Renal Anemia Syndrome: Influence on Neurohormonal Activation and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , 2009, 15, 727-735.	0.7	41
165	Trombopenia e insuficiencia renal aguda tras tratamiento con estreptocinasa. Papel de los esteroides. <i>Revista Espanola De Cardiologia</i> , 1999, 52, 879-881.	0.6	0